AstraZeneca posts $15.29 billion Q1 revenue as cancer drug sales surge

11 articles · Updated · The Wall Street Journal · Apr 29

The UK-based pharmaceutical company reported net profit of $3.08 billion and core earnings per share of $2.58, both surpassing analyst expectations.
Revenue rose 8% year-on-year excluding currency changes, driven by double-digit growth in oncology and rare-disease medicines, with oncology now making up 44% of total revenue.
AstraZeneca reaffirmed its full-year guidance for mid to high single-digit revenue growth and low double-digit core EPS growth, reflecting its ongoing focus on expanding its oncology portfolio.

Can AstraZeneca sustain its rapid revenue growth as U.S. pricing reforms accelerate and competition in cancer drugs intensifies?

With rare disease drug pricing under scrutiny, how will AstraZeneca balance innovation, patient access, and profitability moving forward?

What breakthroughs in AstraZeneca’s oncology pipeline could transform cancer care, and when might patients actually benefit?

How might AstraZeneca's push into China's pharma market reshape global drug development and patient access in the next five years?

Could AstraZeneca’s expansion in obesity and diabetes drugs challenge current leaders, or will regulatory and market risks hold it back?

How will emerging technologies like AI and precision medicine impact AstraZeneca’s ability to stay ahead in drug discovery?